×

Learn About DecisionDx–SCC

Learn About DecisionDx–SCC

Logo_DecisionDx-SCC.png

Learn About DecisionDx–SCC

Cutaneous squamous cell carcinoma (SCC) is the second-most common type of skin cancer, leading to significant surplus mortality. In this webinar, Jason Newman, MD, FACS, Professor of Otorhinolaryngology - Head and Neck Surgery, University of Pennsylvania and director of the Cancer Service Line at Pennsylvania Hospital, explains how DecisionDx-SCC helps improve patient outcomes.

“This 40-GEP test can complement our clinical way of assessing risk for patients, allowing us to make better decisions in the management of their care.”

– Professor Jason Newman, MD, FACS

By the numbers

How SCC impacts patients

1.8M

SCC cases are diagnosed

in the U.S. every year

2-6%

of SCC cases metastasize,

leading to increased mortality

>14,000

annual deaths in the U.S.

are attributed to SCC

By the numbers

How SCC impacts patients

1.8M

SCC cases are diagnosed in the U.S. every year

2-6%

Of SCC cases metastasize, leading to increased mortality

>14,000

Annual deaths in the U.S. are attributed to SCC

What's Next?

Overview

Find essential information and clinical evidence on DecisionDx-SCC.

Order a test

Get informed about the testing process and how to order DecisionDx-SCC.

Scroll to Top